KENBERLY BAUGHMAN: Open Payments
NPI 1275248536 · BOGALUSA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$726 in 7 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $662 · 2025 $726
Food & beverage: $726
| Company | Payments | Amount |
|---|---|---|
| Edwards Lifesciences Corporation | 1 | $142 |
| AstraZeneca Pharmaceuticals LP | 1 | $131 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $97 |
| Novo Nordisk Inc | 1 | $90 |
| Lundbeck LLC | 1 | $19 |
Products named: AIRSUPRA, CAPLYTA, AUSTEDO XR, Kerendia, Wegovy, REXULTI.
Industry payments across LA — which companies pay providers there.
